iymphokine-activated killer cell 9 intercellular adhesion molecule 9 glioma p ATIENTS with malignant glioma have a poor prognosis despite the combined use of surgery, irradiation, chemotherapy, and a variety of immunotherapies. These patients are known to show decreased circulatory immune function and suppression of the tumor-specific immune response. In order to increase host immune function and inhibit tumor growth, many kinds of cytokines, such as interferons, tumor necrosis factors, and interleukins, have been used. In particular, intravenously or intrathecally administered human /3-interferon (HulFN-/3) has been given to patients with malignant glioma since 1980 and its usefulness has been confirmed. 3,1~
Like HulFN-/3, human ~/-interferon (HulFN-7) also has a variety of biological responses in both host and tumor cells. In brain tumors, HulFN-7 has been reported to inhibit in vitro growth of glioma cell lines, 15 to activate the specific cytotoxicity of lymphocytes in the presence of interleukin-2 (IL-2), 1 and to increase the major histocompatibility complex (MHC) surface antigens and some kinds of cell adhesion molecules. 8,9
The MHC antigens and cell adhesion molecules are essential in the control of immune responses functioning in the recognition of antigens by T lymphocytes, u Alterations of the expression of MHC antigens or cell adhesion molecules may result in altered biological behaviors.
On the other hand, lymphokine-activated killer (LAK) cells generated by culturing peripheral blood lymphocytes with IL-2 can lyse a wide variety of tumor cells. Some investigators have reported that IFN-7 potentiated LAK cell cytotoxicity, 2,v,21 but this remains controversial. 24, 25 In the present experiments, we studied the growth-inhibiting effect of in vitro transfection of glioma cells with HulFN-3, gene entrapped in the liposomes and also evaluated the usefulness of combining liposomal transfection and adoptive immunotherapy using LAK cells.
HulFN-~/and LAK cells in human glioma

Materials and Methods
Cell Lines
Cells of the SK-MG-1 and U-251 MG human glioma cell lines were used in this study. The cells were maintained in Eagle's minimum essential medium supplemented with 10% fetal calf serum, 2 mM nonessential amino acids, 5 mM L-glutamine, and antibiotic agents (streptomycin, 100 ~g,/ml, and penicillin, 100 U/ml).
Preparation of Liposome-Entrapped Plasmids
Liposome-entrapped plasmids were prepared by an improved procedure s of the reverse-phase evaporation method, 22 as described in our previous papersJ 2,1s The liposomes were prepared using the positivelycharged lipid N-(ot-trimethylammonio-acetyl)-didodecyl-D-glutamate chloride (TMAG), dilauroyl phosphatidylcholine (DLPC), and dioleoyl phosphatidylethanolamine (DOPE), and were composed in a molar ratio of 1:2:2 as TMAG:DLPC:DOPE. An HulFN-3~ gene inserted into an SV40-derived expression vector (pSVIFN-"/) was used for the plasmid. This was constructed from HindlII-BgllI, large fragments of pSV dihydrofolate reductase (pSVdhfr), HulFN-2/complementary deoxyribonucleic acid (cDNA), and deoxyoligonucleotides.*
Gene Transfection
Two milliliters of SK-MG-1 or U-251 MG cell suspensions was placed in 7.5 • 104 cells/ml culture medium in each well of Falcon No. 3042 plates and incubated at 37~ for 24 hours in a humidified atmosphere of 5% CO 2 and 95% air. After the liposomes or exogenous HulFN-~/t (500 U/ml, titer of 1 X 106 U/ml and specific activity of 3.0 x 10 -7 U/rag of protein) were added to the medium, the solution was incubated at 37~ for 16 hours. Then the medium containing the liposomes was replaced with fresh medium containing no liposomes while the medium containing exogenous HulFN-3, was not replaced, and the incubation was continued for up to 80 hours. The culture medium was collected at 2, 4, 6, and 9 days after mixing with liposomes, and the level of HulFN-'y in the medium was measured by radioimmunoassay. A viable cell count was performed at the same time.
Detection of MHC Antigens and Intercellular Adhesion Molecule-1
Expression of MHC antigens was detected by immunohistochemical study. Cells grown on coverslips were fixed in cold acetone. Mouse anti-MHC class I and II (human leukocyte antigen (HLA)-DR) monoclonal antibodies were applied first for 1 hour, followed by a 30-minute incubation with anti-mouse immunoglobulin (Ig)G monoclonal antibody~ conjugated with horseradish peroxidase. The enzymatic activity was revealed using 0.015 % H202 and 0.4% diaminobenzidine as substrate. Expression of MHC antigens in the glioma cells was studied at 2, 4, 6, and 9 days after adding exogenous HuIFN-7 or liposome-entrapped pSVIFN-~/.
Expression of intercellular adhesion molecule-1 (ICAM-1) was measured using fluorescence-activated cell sorter analysis. The cultured cells (1 X l0 s) were harvested and resuspended in 25 ~1 of a 1:100 dilution of anti-ICAM-1 monoclonal antibody in the complete medium containing 10% fetal calf serum. The cells were incubated for 30 minutes on ice, washed with phosphate-buffered saline (PBS), then incubated for 30 minutes on ice with a 1:20 dilution of fluorescein isothiocyanate-labeled goat anti-mouse IgG monoclonal antibody.w Thereafter, the cells were washed with PBS three times and resuspended in 0.5 ml PBS. Fluorescence was quantitated using the EPICS profile software.II
Generation of LAK Cells
Peripheral blood lymphocytes were obtained from healthy allogeneic donors. Heparinized peripheral blood was diluted 1:1 with PBS, and lymphocytes were separated by Ficoll-Paque gradient centrtfugation. The cells collected at the gradient interface, designated as peripheral blood lymphocytes, were washed three times with PBS, then resuspended in complete medium consisting of RPMI 1640 containing 10% fetal calf serum, 2 mM L-glutamine, antibiotic agents (streptomycin, 100/xg/ml, and penicillin, 100 U/ml), and IL-2 (10 U/ml). The peripheral blood lymphocytes were activated to generate LAK cells by Day 5 of incubation.
Combined Application of HulFN-3~ Gene Transfection and LAK Cells
At first, we applied either exogenous HulFN-~/(500 U/ml) or liposome-entrapped pSVIFN-y (15 nmol/ml of lipids; 0.6 /xg/ml of DNA) to each well. For the former treatment, glioma cells were incubated for 4 days without medium changes; for the latter, the cells were incubated with liposomes for 16 hours and the medium was then replaced with fresh medium containing no liposomes, after which the incubation was continued for up to 80 hours. The culture medium in both treatments was collected 4 days after adding reagents, and the level of HulFN-',/in the medium was measured. At the same time, the cells were counted and LAK cells were applied at a 5:1 ratio of effector to target cells. After an additional 2 days of incubation, the results of combined application were evaluated. * TMAG obtained from Sogo Pharmaceutical Co., Ltd., Tokyo, Japan; DLPC supplied by Sigma Chemical Co., St. Louis, Missouri; DOPE obtained from Avanti Polar Lipids, Inc., Pelham, Alabama; pSVIFN-~, plasmid constructed by Toray Industries, Inc., Tokyo, Japan.
t Natural HulFN-'y obtained from Ohtsuka Pharmaceutical Co., Ltd., Tokyo, Japan.
:~ Mouse anti-MHC and anti-mouse IgG monocional antibodies obtained from Dakopatts, Glostrup, Denmark.
w Anti-ICAM-1 monoclonal antibody obtained from British Biotechnology Products, lnc., Oxford, England; goat anti-mouse IgG monoclonal antibody supplied by Medical and Biological Laboratories Co., Ltd., Nagoya, Japan.
II EPICS software obtained from Coulter Corp., Hialeah, Florida. * Data are taken from six experiments and expressed as mean -+ standard deviation. HulFN-3, = human "y-interferon; pSVIFN-7 = SV40-derived expression vector with HulFN-7 gene insertion.
Growth Inhibition
Inhibition of gene transfection and/or LAK cell growth was evaluated by determining the number of viable cells, expressed as the number of trypan blueexcluding cells counted in a hemocytometer. The inhibition (% cytotoxicity) of gene transfection and/or LAK cell growth was determined with the following formula:
number of cells in target well % cytotoxicity = 1 number of cells in control well X 100.
Results
Production of HulFN-7 in Glioma Cells Transfeeted With pSVIFN-7
When glioma cells were transfected with pSVIFN-7 by means of liposomes and incubated for 4 days, HulFN-7 was detected via radioimmunoassay in the media of both SK-MG-1 and U-251 MG cells. The HulFN-7 was detected at 2 days after transfection and reached a maximum after 4 days. Thereafter, it gradually decreased and was not detected at all by 9 days after transfection. The maximum level of HulFN-7 in the medium was 41.3 __ 5.5 U/ml (mean +_ standard deviation) in SK-MG-1 cells and 19.3 _+ 6.1 U/ml in U-251 MG cells (Table 1) . On the other hand, HuIFN-',/ was not detected in the culture medium in either SK-MG-1 or U-251 MG cells when empty liposomes were added to the medium.
Expression of MHC Antigens or ICAM-1 on Glioma Cells
The MHC class I and II (HLA-DR) antigens were negative at the first passage of culture, but could be induced to express MHC antigens for 2 to 6 days after adding more than 50 U/ml exogenous HuIFN-7. This was confirmed by immunohistochemical staining. Similarly, the antigens could be detected on glioma cell surfaces during the same time periods when liposomeentrapped pSVIFN-3, was added to the medium, even though the level of HuIFN-7 in the medium was less than 50 U/ml.
Expression of ICAM-1 was detected by fluorescence-activated cell sorter analysis. It was not expressed in either SK-MG-1 or U-251 MG cells when the cells were untreated. However, it was detected on M. Mizuno, et al. glioma cell surfaces when liposome-entrapped pSVIFN-7 was added to the medium and the cells were incubated for 4 days (Fig. 1) .
Growth Inhibition
Empty liposomes did not significantly suppress the growth of either SK-MG-1 or U-251 MG cells; however, liposome-entrapped pSVIFN-7 suppressed cell growth remarkably. Compared with the growth-inhibiting effect of exogenous HulFN-7 (500 U/ml), the effect of gene transfection was obviously stronger and was cytocidal (Fig. 2) , although the level of HulFN-3, in the culture medium was very low ( Table 1) .
The glioma cells were cultured for 4 days after adding exogenous HulFN-'y or transfection of its gene. Four days after the reagents were added, the culture medium was collected and the number of viable cells counted. Thereafter, LAK cells were applied at an effector-to-target cell ratio of 5:1. After an additional 2 days of incubation, the growth-inhibiting effect was evaluated by determining the number of viable cells. As shown in Fig. 3 , glioma cells transfected with pSVIFN-7 were suppressed by LAK cells more efficiently than those incubated with exogenously added HulFN-% The combined therapy of HulFN-7 gene transfection followed by adoptive immunotherapy using LAK cells resulted in a synergistic growth-inhibiting effect in both SK-MG-1 and U-251 MG cells. The reinforcement of growth inhibition in the case of the combined therapy was partially quenched by anti-ICAM-1 monoclonal antibody (Fig. 4) , but not by anti-MHC class I or class II monoclonal antibody (data not shown).
Discussion
Recently, a number of biological response modifiers have emerged as potentially useful agents in patients with malignant ghoma. In 1980, intravenous or intrathecal administration of IFN's was introduced for the treatment of malignant glioma following both in vitro and in vivo demonstrations of its efficacy. 3,1~ Interferons have a definite direct growth-inhibiting effect on glioma cells and modulate the expression of the cell surface antigens, including MHC antigens and cell adhesion molecules, thus providing a potential regulatory mechanism for local immune reactivity. 16,17,23 Gammainterferon in particular has very strong immunoreactivities.
In this study, we investigated the alteration of cell surface antigens and the reinforced effect of cytotoxicity of LAK cells when HulFN-'/gene was transfected into glioma cells, which then continuously produced HulFN lo trace. Our data indicated that induction of MHC antigens on the glioma cell surface was not related to the cytotoxicity of LAK ceils, because the reinforcement of LAK cytotoxicity that was induced by HulFN-~," gene transfection into the glioma cells was not neutralized by anti-MHC class I or class II monoclonal antibodies. On the other hand, ICAM-1, which belongs in the immunoglobulin superfamily, seems to be an important agent because the reinforcement of LAK cytotoxicity was partially canceled by anti-ICAM-1 monoclonal antibody.
The adoptive immunotherapy reported by Rosenberg and colleagues 1s,19 was effective in patients with advanced cancer, but several studies have reported that adoptive immunotherapy is not satisfactory because LAK cells may become trapped in the reticular formation and thus cannot reach the target cells. However, in our patients with malignant glioma, it has been possible to administer liposomes and/or LAK cells into the tumor cavity repeatedly through an Ommaya reservoir placed at surgery. The procedure seems to ensure longterm expression of the HulFN-'y gene product in the patient. Moreover, we are studying the reinforcement of LAK cytotoxicity with bifunctional antibodies, which are composed of anti-CD3 monoclonal antibody Ft6. 2. Graphs showing growth inhibition of human glioma cells by exogenous human ~/-interferon (HulFN-y) or transfection of its gone. Open circles = untreated control cells; closed circles = empty liposomes (15 nmol/ml lipids); triangles = exogenous HulFN-y (500 U/ml); and squares = liposome-entrapped SV40-derived expression vector with HulFN-7 gene insertion (pSVIFN-~/) (15 nmol/ml lipids, 0.6 /~g/ml DNA). Each symbol represents the mean of six experiments. In both SK-MG-1 and U-251 MG cells, the growthinhibiting effect of HulFN-7 gene transfection was much stronger than that of 500 U/ml exogenous HulFN-',/, to the extent of being cytocidal. and anti-G-22 monoclonal antibody 13 that reacts specifically with a surface antigen (G-22) of human glioma. We have confirmed an increase in affinity of gene-transfected glioma cells and L A K cells using the bifunctional antibodies; details will be reported at a later date. These results suggest that combining liposomal transfection of HulFN-7 gone into human glioma cells with the addition of L A K cells is a potentially useful therapy for malignant glioma.
